HIV and prostate cancer: A systematic review of the literature

Prostate Cancer and Prostatic Diseases

Volumn 12, Issue 1, 2009, Pages 6-12

  Silberstein, J ^a   Downs, T ^a,b,c   Lakin, C ^a,c   Kane, C J ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ANTIRETROVIRUS AGENT; IMMUNOSUPPRESSIVE AGENT; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACUTE DISEASE; ADJUVANT THERAPY; BRACHYTHERAPY; CANCER GRADING; CANCER INCIDENCE; CANCER STAGING; CANCER SURVIVAL; CD4 LYMPHOCYTE COUNT; CLINICAL FEATURE; CLINICAL PROTOCOL; CLINICAL TRIAL; CRYOSURGERY; DIGITAL RECTAL EXAMINATION; DISEASE ASSOCIATION; DISEASE COURSE; EXTERNAL BEAM RADIOTHERAPY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOGONADISM; INCIDENCE; INTENSITY MODULATED RADIATION THERAPY; KAPOSI SARCOMA; KIDNEY GRAFT REJECTION; LAPAROSCOPIC SURGERY; LYMPH NODE METASTASIS; MEDICAL LITERATURE; MEDLINE; MORBIDITY; NONHODGKIN LYMPHOMA; PATIENT SAFETY; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RADICAL RETROPUBIC PROSTATECTOMY; RECTUM CANCER; REVIEW; SURVIVAL TIME; SYMPTOM; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UROLOGIC EXAMINATION; VIRUS LOAD;

AGED; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS;

EID: 60349109799     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2008.44     Document Type: Review

References (42)

1. Engels EA, Pfeiffer RM, Goedert JJ, Virgo P, McNeel TS, Scoppa SM et al. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS 2006; 20: 1645.
2. Goedert JJ, Purdue MP, McNeel TS, McGlynn KA, Engels EA. Risk of germ cell tumors among men with HIV/acquired immunodeficiency syndrome. Cancer Epidemiol Biomarkers Prev 2007; 16: 1266.
3. Goedert JJ, Schairer C, McNeel TS, Hessol NA, Rabkin CS, Engels EA. Risk of breast, ovary, and uterine corpus cancers among 85 268 women with AIDS. Br J Cancer 2006; 95: 642.
4. Glynn M, Rhodes P. Estimated HIV prevalence in the United States at the end of 2003. National HIV Prevention Conference. Atlanta, GA, 2005.
5. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report, 2006. US Department of Health and Human Services, Centers for Disease Control and Prevention: Atlanta, GA, vol. 18, 2008. http://www.cdc.gov/hiv/topics/surveillance/ resources/reports/2006report/ default.htm
6. Centers for Disease Control and Prevention. Trends in HIV/ AIDS diagnoses - 33 states, 2001-2004. MMWR Morb Mortal Wkly Rep 2005; 54: 1149.
7. Hessol NA, Pipkin S, Schwarcz S, Cress RD, Bacchetti P, Scheer S. The impact of highly active antiretroviral therapy on non-AIDS-defining cancers among adults with AIDS. Am J Epidemiol 2007; 165: 1143.
8. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71.
9. Ng T, Stein NF, Kaminetsky J, Berman S, Marans HY, McDermott B et al Preliminary results of radiation therapy for prostate cancer in human immunodeficiency virus-positive patients. Urology 2008. [E-pub ahead of print].
10. Pantanowitz L, Bohac G, Cooley TP, Aboulafia D, Dezube BJ. Human immunodeficiency virus-associated prostate cancer: Clinicopathological findings and outcome in a multi-institutional study. BJU Int 2008; 101: 1519-1523.
11. Walters Z, Shamash J, Powles T. Prostate cancer in HIV-positive individuals: What we know and what we don't. J HIV Ther 2007; 12: 66.
12. Manfredi R, Fulgaro C, Sabbatani S, Dentale N, Legnani G. Disseminated, lethal prostate cancer during human immunodeficiency virus infection presenting with non-specific features. Open questions for urologists, oncologists, and infectious disease specialists. Cancer Detect Prev 2006; 30: 20.
13. Huang WC, Kwon EO, Scardino PT, Eastham JA. Radical prostatectomy in patients infected with human immunodeficiency virus. BJU Int 2006; 98: 303.
14. O'Connor JK, Nedzi LA, Zakris EL. Prostate adenocarcinoma and human immunodeficiency virus: Report of three cases and review of the literature. Clin Genitourin Cancer 2006; 5: 85.
15. Quatan N, Nair S, Harrowes F, Hay P. Should HIV patients be considered a high risk group for the development of prostate cancer? Ann R Coll Surg Engl 2005; 87: 437.
16. Levinson A, Nagler EA, Lowe FC. Approach to management of clinically localized prostate cancer in patients with human immunodeficiency virus. Urology 2005; 65: 91.
17. Crum NF, Spencer CR, Amling CL. Prostate carcinoma among men with human immunodeficiency virus infection. Cancer 2004; 101: 294.
18. Furco A, Bani-Sadr F, Guymar S, Molina JM. [Metastatic cancer of the prostate in a young 40 year-old HIV-infected male patient]. Presse Med 2003; 32: 930.
19. Staiman V, Lowe FC. Prostatic disease in HIV-infected patients. Infections in Urology 1996; 42.
20. Schwartz JD, Prince D. Prostate cancer in HIV infection. AIDS 1996; 10: 797-798.
21. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 43.
22. Ries LAG, Melbert D, Krapcho M, Mariotto A, Miller BA, Feuer EJ, Clegg L, Horner MJ, Howlader N, Eisner MP, Reichman M, Edwards BK (eds). SEER Cancer Statistics Review, 1975-2004. National Cancer Institute: Bethesda, MD. http://seer.cancer.gov/esr/1975_2004/
23. Biggar RJ, Kirby KA, Atkinson J, McNeel TS, Engels E. Cancer risk in elderly persons with HIV/AIDS. J Acquir Immune Defic Syndr 2004; 36: 861.
24. Frisch M, Biggar RJ, Engels EA, Goedert JJ, AIDS-Cancer Match Registry Study Group. Association of cancer with AIDS-related immunosuppression in adults. JAMA 2001; 285: 1736.
25. Gallagher B, Wang Z, Schymura MJ, Kahn A, Fordyce EJ. Cancer incidence in New York State acquired immunodeficiency syndrome patients. Am J Epidemiol 2001; 154: 544.
26. Burgi A, Brodine S, Wegner S, Milazzo M, Wallace MR, Spooner K et al Incidence and risk factors for the occurrence of non- AIDS-defining cancers among human immunodeficiency virus-infected individuals. Cancer 2005; 104: 1505.
27. Brenner H, Arndt V. Long-term survival rates of patients with prostate cancer in the prostate-specific antigen screening era: Population-based estimates for the year 2000 by period analysis. J Clin Oncol 2005; 23: 441.
28. de Koning HJ, Liem MK, Baan CA, Boer R, Schroder FH, Alexander FE. Prostate cancer mortality reduction by screening: Power and time frame with complete enrollment in the European Randomised Screening for Prostate Cancer (ERSPC) trial. Int J Cancer 2002; 98: 268.
29. Gohagan JK, Prorok PC, Hayes RB, Kramer BS. The prostate, lung, colorectal and ovarian (PLCO) cancer screening trial of the National Cancer Institute: History, organization, and status. Control Clin Trials 2000; 21: 251S.
30. Jensen AR, Garne JP, Storm HH, Ewertz M, Cold S, Alvegaard T et al Stage and survival in breast cancer patients in screened and non-screened Danish and Swedish populations. Acta Oncol 2003; 42: 701.
31. Prostate-specific antigen (PSA) best practice policy. American Urological Association (AUA). Oncology (Williston Park) 2000; 14: 267.
32. Lohse N, Hansen AB, Gerstoft J, Obel N. Improved survival in HIV-infected persons: Consequences and perspectives. J Antimicrob Chemother 2007; 60: 461.
33. Schackman BR, Gebo KA, Walensky RP, Losina E, Muccio T, Sax PE et al The lifetime cost of current human immunodeficiency virus care in the United States. Med Care 2006; 44: 990.
34. Wammack R, Djavan B, Remzi M, Susani M, Marberger M. Morbidity of transrectal ultrasound-guided prostate needle biopsy in patients receiving immunosuppression. Urology 2001; 58: 1004.
35. Vianna LE, Lo Y, Klein RS. Serum prostate-specific antigen levels in older men with or at risk of HIV infection. HIV Med 2006; 7: 471.
36. Kwan DJ, Lowe FC. Genitourinary manifestations of the acquired immunodeficiency syndrome. Urology 1995; 45: 13.
37. Crum NF, Furtek KJ, Olson PE, Amling CL, Wallace MR. A review of hypogonadism and erectile dysfunction among HIV-infected men during the pre- and post-HAART eras: Diagnosis, pathogenesis, and management. AIDS Patient Care STDS 2005; 19: 655.
38. Rhoden EL, Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med 2004; 350: 482.
39. Simon V, Ho DD, Abdool KQ. HIV/AIDS epidemiology, pathogenesis, prevention, and treatment. Lancet 2006; 368: 489.
40. Engels EA, Biggar RJ, Hall HI, Cross H, Crutchfield A, Finch JL et al Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer 2008; 123: 187.
41. Klein EA, Silverman R. Inflammation, infection, and prostate cancer. Curr Opin Urol 2008; 18: 315.
42. Pajonk F, Himmelsbach J, Riess K, Sommer A, McBride WH. The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIV-associated human cancer cells. Cancer Res 2002; 62: 5230.